<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
	<title>I.DRUGS USED TO TREAT PEPTIC ULCER DISEASE AND GASTROESOPHAGEAL REFLUX DISEASE</title>
	<meta name='Generator' content='Zim 0.73.1'>
	<style type='text/css'>
		a          { text-decoration: none      }
		a:hover    { text-decoration: underline }
		a:active   { text-decoration: underline }
		strike     { color: grey                }
		u          { text-decoration: none;
					 background-color: yellow   }
		tt         { color: #2e3436;            }
		pre        { color: #2e3436;
					 margin-left: 20px          }
		h1         { text-decoration: underline;
					 color: #4e9a06; margin-bottom: 0 }
		h2         { color: #4e9a06; margin-bottom: 0 }
		h3         { color: #4e9a06; margin-bottom: 0 }
		h4         { color: #4e9a06; margin-bottom: 0 }
		h5         { color: #4e9a06; margin-bottom: 0 }
		p          { margin-top: 0              }
		span.zim-tag {
			color: #ce5c00;
		}
		div.zim-object {
			border-style:solid;
			border-width:1px;
		}
		.checked-box {list-style-image: url(data:image/png;base64,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)}
		.xchecked-box {list-style-image: url(data:image/png;base64,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)}
		.unchecked-box {list-style-image: url(data:image/png;base64,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)}
		.migrated-box {list-style-image: url(data:image/png;base64,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)}
		ul {list-style-image: none}
		/* ul rule needed to reset style for sub-bullets */
	</style>
</head>
<body>

<!-- Header -->
<div class='header'>
	[ <a href='./Pharmacognosy.html'>Prev</a> ]

	[ <span class='insen'>Index</span> ]

	[ <a href='..\4.html'>Next</a> ]
</div>

<hr />

<!-- Wiki content -->

<div class='pages'>
	<div class='heading'>
	<h1>I.DRUGS USED TO TREAT PEPTIC ULCER DISEASE AND GASTROESOPHAGEAL REFLUX DISEASE <a name='3:Pharmacology'></a></h1>
	</div>

	<div class='content'>
	
<br>

<p>
OVERVIEW:<br>
<img src="./Pharmacology/pasted_image.png">
</p>

<h1>II.  DRUGS USED TO TREAT PEPTIC ULCER DISEASE AND GASTROESOPHAGEAL REFLUX DISEASE</h1>

<br>

<h3>⇒ FACTORS:</h3>

<p>
<ul>
<li>G- Helicobacter pylori</li>
<li>NSAIDS</li>
<li>↑ hydrochloric acid secretion</li>
<li>inadequate mucosal defense against gastric acid</li>
</ul>
</p>

<h3>⇒ TREATMENT APPROACHES</h3>

<p>
<ol type="A" start="1">
<li><b>ANTIMICROBIAL AGENTS:</b></li>
</ol>
pylori requires antimicrobial treatment<br>
<ul>
<li>iple therapy —   PPI +  <i>metronidazole or amoxicillin + clarithromycin</i></li>
<li>quadruple therapy —  <i>bismuth subsalicylate</i> + <i>metronidazole+etracycline + PPI,</i> a 2-week course.           </li>
</ul>
<div style='padding-left: 270pt'>
→ do not neutralize stomach acid, but  inhibit  pepsin and increase the secretion of mucus.
</div>
<div style='padding-left: 480pt'>
 ( barrier against the diffusion of acid in the ulcer)
</div>
<b>B.H2-RECEPTOR ANTAGONIST:</b><br>
→ reuglation of gastric acid secration <br>
<img src="./Pharmacology/pasted_image001.png">
</p>

<p>
 → acid secration stimulated by<br>
 — <i>acetylcholine — histamine — gastrin</i> — <br>
→ activation of adenylyl cyclase → stimualtes H/K+-ATPase proton pump to secrete hydrogens ions in exchange of K+ into the lumen of the stomach<br>
→ Prostagladins + somatostasin diminish gastric acid production
</p>

<p>
⇒ AGENTS:<br>
→ <i>CLIMETIDINE </i> RANITIDINE <i> FAMOTIDINE </i> NIZATIDINE  (potently inhibitors 90%)//
</p>

<p>
1.ACTIONS:
</p>

<p>
<ul>
<li>act selectively on H2 receptors in the stomach, blood vessels, and other sites no effect on H1 receptors. </li>
<li>competitive antagonists of histamine and are fully reversible.</li>
</ul>
</p>

<p>
2.THERAPEUTIC USE: <b>(</b>usage of these agents has decreased with the  advent of ppis)
</p>

<p>
a.Peptic uclers:<br>
<ul>
<li>promoting the healing of duodenal and gastric ulcers</li>
</ul>
b.Acute stress uclers:<br>
<ul>
<li>I.V. admn. prevent + manage actue stress uclers</li>
</ul>
c.GERD:<br>
<ul>
<li>low doses(OTC) → preventaion and treatment of heartburn.</li>
</ul>
3.PHARMACOKINETIC:
</p>

<p>
a.//CLIMETEIDINE://<br>
<ul>
<li>Orally amdn.</li>
<li>distribute widely through the body (including breat milk and placenta)</li>
<li>exreted mainly in urine</li>
<li>short-serum half-lifef (which ↑ renal failure)</li>
<li>30% slowly inactivated by the livers oxygensae system (interfere with other drugs)</li>
<li>70% unchanged in urine </li>
<li>inhibit C-450 and can slow or potentiate metabolism of other durgs (warfarin,diazepam,phenytoin,quinidie,theophylline etc)</li>
</ul>
b.//RANITIDINE://<br>
<ul>
<li>longer acting than Clim + more potent </li>
<li>minimal side effects ( does not inhibit oxygenase system and does affect concentration of other durgs)</li>
</ul>
c.//FAMOTIDINE://<br>
<ul>
<li>3 to 20 times more potent than Ranitidine</li>
</ul>
d.NIZATIDINE:<br>
<ul>
<li>metabolized by the kidneys</li>
<li>bioavailability is nearly 100%</li>
</ul>
</p>

<p>
4.ADVERSE EFFECT
</p>

<p>
<ul>
<li>reduced gastric acid production</li>
<li>headache,dizziness,diarrhea and muscular pain</li>
<li>confusion and hallugination when admn.IV. in elderly patients</li>
<li>gymecomastia and galactorrhea</li>
<li>ketoconazole which depends on an acidic medium for gastric absorbtion .</li>
</ul>
</p>

<p>
<b>C.PROTON PUMP INHIBITORS PPIs</b>
</p>

<p>
→  Inhibitors of the H+/K+-ATPase proton pump → supress secretion hydrogens ions 
</p>

<p>
AGENTS:<br>
→ <i>OMEPRAZOLE </i> DEXLANSOPRAZOLE <i> ESOMEPRAZOLE </i> LANSOPRAZOLE <i> PANTOPRAZOLE  </i> RABEPRAZOLE//
</p>

<p>
1.ACTIONS:<br>
<ul>
<li>pro-drugs with an acidic-resistant enteric coating to protect them form premature degradtion by gastric acid</li>
<li>coating removed in the alkaline duodenum → and the weak base asborbed and trasport to the parietal cell</li>
<li>active form react with H/K ATPase</li>
<li>18hrs to be resynthesized</li>
<li>omeprazole + sodium bicarbonate for faster absorbtion (OTC)</li>
</ul>
</p>

<p>
2.THERAPEUTIC USES:
</p>

<p>
<ul>
<li>Stress ulcer treatment and prophylaxis</li>
<li>treating erosive esophagitis </li>
<li>active duodenal ulcer</li>
<li>Zollinger-Ellison syndrome</li>
<li>GERD</li>
<li>should be taken 30 to 60 minutes before breakfast or the largest meal of the day</li>
<li>h2-receptor antagonist after PPI's (cuz h2 will reduce the proton pump activity)</li>
</ul>
</p>

<p>
3.PHARMACOKINETICS<br>
<ul>
<li>effective orally </li>
<li>metabolites of these agents excreted in urine and feces</li>
</ul>
</p>

<p>
4.ADVERSE EFFECT<br>
<ul>
<li>decrease the effectiveness of clopidogrel due to inhibition of CYP2C19</li>
<li>Omeprazole has been shown to inhibit the metabolism of warfarin, phenytoin, diazepam, and cyclosporine through competitive inhibition of CYP450 </li>
<li>low vitamin B12</li>
<li>Incomplete absorption of calcium carbonate product → CALCIUM CITRATE is the solution since citrate salt does not affect gastric pH</li>
<li>diarrhea</li>
</ul>
</p>

<p>
<b>D.PROSTAGLADINS</b>
</p>

<p>
⇒ Misoprostol<br>
<ul>
<li>prostagladin E analogue</li>
<li>less effective than h2.PPIs </li>
<li>cytoprotective actins ( inhibits secretion of HCL and stimulates secretion of mucus and bicarbonate)</li>
<li>produce uterine contractions and logdging of the fetus and is CONTRAINDICATED to pregnancy</li>
<li>diarhea and nausea is the most common adverse effect</li>
</ul>
</p>

<p>
<b>E.ANTACIDS:</b>
</p>

<p>
→ Weak bases react with gatric acid to form water and a salt to dimish gastric acidity<br>
<ul>
<li>pepsin is inactive at a pH greater than 4↓ pespsin activity </li>
</ul>
</p>

<p>
1.CHEMISTRY<br>
<ul>
<li>acid-neutralizing ability depends on whether the stomach is full or empty ( full stomach more time for antacid to react)</li>
</ul>
→commonly salts of alluminium and magnesium<br>
⇒ <i>ALUMINUM HYDROXIDE </i> MAGNESIUM HYDROXIDE  <i> CALCIUM CARBONATE ( </i>reacts with HLC to form CO2 and CaCl2 and its commonly used preparation)
</p>

<p>
2.THERAPEUTIC USE:<br>
<ul>
<li>symptomatic relief of peptic ulcer + GERD // may also promote healing of duodenal ucler.</li>
</ul>
</p>

<p>
3.ADVERSE EFFECTS:<br>
<ul>
<li>Al(OH)3 → constipation</li>
<li>Mg(OH)2 →diarhhea</li>
<li>NaHCO3 → systematic absorption produce  <i> metabolic alkalosis </i> bleching + flatulence</li>
<li>ad may occur in patients with renal impairment due to acumulation of cations</li>
</ul>
</p>

<p>
  <b>F.MUSCOSAL PROTECTIVE AGENTS:</b><br>
→ cytoprotective compounds <br>
<ul>
<li>enchance mucosal protection <i> preventing mucosal injury </i> reducing inflammation // healing existing ulcers</li>
</ul>
</p>

<p>
1.//SUCRALFATE://<br>
<ul>
<li>complex of aluminum hydroxide and sulfated sucrose</li>
</ul>
→ bind to + charged group in proteins ( normal and necrotic muscosa)<br>
→ forming complex gels with epithelial cells<br>
→ create a physical barrier that impairs diffusion of HCL and prevents degradation of mucus by pepsin<br>
→ stimulate PG release and inhibit peptic digestion<br>
<ul>
<li>requires acidic enviroment and absorbed systemically with good tolerance</li>
</ul>
</p>

<p>
2.//BISMUTH SUBSALICYLATE://<br>
<ul>
<li>heal peptic ulcer</li>
<li>inhibit activity of pepsin <i> ↑ secration of mucus </i> coat and protect the ulcer crater</li>
</ul>
</p>

	</div>

	<br />

	<div class='page-footer'>

			<b>Attachments:</b>
			<table>

			<tr><td><a href='./Pharmacology/pasted_image.png'>pasted_image.png</a></td><td>&nbsp;</td><td>89.5kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image001.png'>pasted_image001.png</a></td><td>&nbsp;</td><td>250kb</td></tr>

			</table>
	</div>

	

</div>

</body>
</html>
